(Q37581507)

English

Profile of changes in bone turnover markers during once-weekly teriparatide administration for 24 weeks in postmenopausal women with osteoporosis

scientific article published on 10 October 2013

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

21 August 2017

Profile of changes in bone turnover markers during once-weekly teriparatide administration for 24 weeks in postmenopausal women with osteoporosis (English)

1 reference

Europe PubMed Central

PMC publication ID

21 August 2017

0 references

author name string

T Sugimoto

1

1 reference

Europe PubMed Central

PMC publication ID

21 August 2017

T Nakamura

2

1 reference

Europe PubMed Central

PMC publication ID

21 August 2017

Y Nakamura

3

1 reference

Europe PubMed Central

PMC publication ID

21 August 2017

Y Isogai

4

1 reference

Europe PubMed Central

PMC publication ID

21 August 2017

M Shiraki

5

1 reference

Europe PubMed Central

PMC publication ID

21 August 2017

language of work or name

0 references

publication date

10 October 2013

1 reference

Europe PubMed Central

PMC publication ID

21 August 2017

Osteoporosis International

1 reference

Europe PubMed Central

PMC publication ID

21 August 2017

25

1 reference

Europe PubMed Central

PMC publication ID

21 August 2017

3

1 reference

Europe PubMed Central

PMC publication ID

21 August 2017

1173-1180

1 reference

Europe PubMed Central

PMC publication ID

21 August 2017

copyright license

Creative Commons Attribution-NonCommercial 2.0 Generic

10 October 2013

1 reference

April 2022 Public Data File from Crossref

copyright status

0 references

https://scigraph.springernature.com/pub.10.1007/s00198-013-2516-1

0 references

Effects of a single injection of teriparatide on bone turnover markers in postmenopausal women

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3923119

23 August 2017

Relationship between bone mineral density changes with denosumab treatment and risk reduction for vertebral and nonvertebral fractures.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3923119

23 August 2017

Parathyroid hormone as an anabolic therapy for women and men.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3923119

23 August 2017

The anabolic effects of parathyroid hormone therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3923119

23 August 2017

Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3923119

23 August 2017

Increased bone formation by prevention of osteoblast apoptosis with parathyroid hormone

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3923119

23 August 2017

Canine renal receptors for parathyroid hormone. Down-regulation in vivo by exogenous parathyroid hormone

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3923119

23 August 2017

Parathyroid hormone increases beta-catenin levels through Smad3 in mouse osteoblastic cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3923119

14 September 2017

Characterization and agonist-induced down-regulation of parathyroid hormone receptors in clonal rat osteosarcoma cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3923119

28 September 2017

Effects of teriparatide on bone mineral density and bone turnover markers in Japanese subjects with osteoporosis at high risk of fracture in a 24-month clinical study: 12-month, randomized, placebo-controlled, double-blind and 12-month open-label ph

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3923119

25 June 2018

Down-regulation of parathyroid hormone (PTH) receptors in cultured bone cells is associated with agonist-specific intracellular processing of PTH-receptor complexes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3923119

25 June 2018

Changes in the contents of enzymatic immature, mature, and non-enzymatic senescent cross-links of collagen after once-weekly treatment with human parathyroid hormone (1-34) for 18 months contribute to improvement of bone strength in ovariectomized m

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3923119

1 September 2018

Histomorphometric changes by teriparatide in alendronate-pretreated women with osteoporosis.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3923119

1 September 2018

Opposite bone remodeling effects of teriparatide and alendronate in increasing bone mass

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3923119

1 September 2018

Comparison of the action of transient and continuous PTH on primary osteoblast cultures expressing differentiation stage-specific GFP.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3923119

1 September 2018

Relationship between changes in bone mineral density and vertebral fracture risk associated with risedronate: greater increases in bone mineral density do not relate to greater decreases in fracture risk

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3923119

1 September 2018

The effect of teriparatide [human parathyroid hormone (1-34)] therapy on bone density in men with osteoporosis.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3923119

1 September 2018

Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3923119

1 September 2018

Relationships between bone mineral density and incident vertebral fracture risk with raloxifene therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3923119

1 September 2018

Parathyroid hormone as a therapy for idiopathic osteoporosis in men: effects on bone mineral density and bone markers.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3923119

1 September 2018

Effect of an intermittent weekly dose of human parathyroid hormone (1-34) on osteoporosis: a randomized double-masked prospective study using three dose levels

1 reference

https://pubmed.ncbi.nlm.nih.gov/24108429

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Randomized Teriparatide [human parathyroid hormone (PTH) 1-34] Once-Weekly Efficacy Research (TOWER) trial for examining the reduction in new vertebral fractures in subjects with primary osteoporosis and high fracture risk

1 reference

https://pubmed.ncbi.nlm.nih.gov/24108429

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Catabolic effects of continuous human PTH (1--38) in vivo is associated with sustained stimulation of RANKL and inhibition of osteoprotegerin and gene-associated bone formation

1 reference

https://pubmed.ncbi.nlm.nih.gov/24108429

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Hormonal control of bone collagen synthesis in vitro: effects of parathyroid hormone and calcitonin

1 reference

https://pubmed.ncbi.nlm.nih.gov/24108429

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Parathyroid hormone reversibly suppresses the differentiation of osteoprogenitor cells into functional osteoblasts

1 reference

https://pubmed.ncbi.nlm.nih.gov/24108429

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Increased bone formation by intermittent parathyroid hormone administration is due to the stimulation of proliferation and differentiation of osteoprogenitor cells in bone marrow

1 reference

https://pubmed.ncbi.nlm.nih.gov/24108429

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Coordinate regulation of PTH/PTHrP receptors by PTH and calcitriol in UMR 106-01 osteoblast-like cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/24108429

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Down-regulation of the receptor for parathyroid hormone (PTH) and PTH-related peptide by PTH in primary fetal rat osteoblasts

1 reference

https://pubmed.ncbi.nlm.nih.gov/24108429

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Parathyroid hormone regulates osteoblast differentiation positively or negatively depending on the differentiation stages

1 reference

https://pubmed.ncbi.nlm.nih.gov/24108429

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Change in lumbar spine BMD and vertebral fracture risk reduction in teriparatide-treated postmenopausal women with osteoporosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/24108429

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Rapid and robust response of biochemical markers of bone formation to teriparatide therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/24108429

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Relationship of changes in total hip bone mineral density to vertebral and nonvertebral fracture risk in women with postmenopausal osteoporosis treated with once-yearly zoledronic acid 5 mg: The HORIZON-Pivotal Fracture Trial (PFT)

1 reference

https://pubmed.ncbi.nlm.nih.gov/24108429

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S00198-013-2516-1

1 reference

Europe PubMed Central

PMC publication ID

21 August 2017

release_ksee3axfybbxlptcsxezmnc33a

1 reference

https://api.fatcat.wiki/v0/release/ksee3axfybbxlptcsxezmnc33a

24 November 2022

based on heuristic

mapped directly with Wikidata item

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

21 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

21 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37581507&oldid=2176808278"